Navigation Links
ProUroCare Medical Inc. Announces Pricing of Equity Offering
Date:1/9/2009

GOLDEN VALLEY, Minn., Jan. 9 /PRNewswire-FirstCall/ -- ProUroCare Medical Inc. (OTC Bulletin Board: PUMD) announces the public offering of 3,050,000 units at $1.00 per unit, each unit consisting of one share of common stock and one redeemable warrant to purchase one share of common stock at an exercise price of $1.30 per share. The Company has granted the underwriter of the offering a 45-day option to purchase up to an additional 457,500 units to cover over-allotments, if any. The offering is expected to close on or about January 12, 2009.

The offering is being underwritten on a firm commitment basis by Feltl and Company, Inc.

Net proceeds of this offering will be used to fund certain operating expenses and development costs as the Company pursues FDA 510(k) clearance of its ProUroScan(TM) prostate imaging system and to retire certain short-term liabilities.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock or any other securities, nor will there be any sale of the shares of common stock or any other securities in any state of jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus forming a part of the effective registration statement.

Copies of the final prospectus relating to the offering may be obtained from Feltl and Company, Inc., 225 South Sixth Street, Suite 4200, Minneapolis, MN 55402.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a development stage company engaged in the business of developing for market innovative products for the detection and characterization of male urological prostate disease. The Company's primary focus is currently the ProUroScan prostate imaging system, which is now in clinical trials.


'/>"/>
SOURCE ProUroCare Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
2. Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients
3. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
7. Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
8. Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora
9. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
10. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
11. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... ... of the CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface ... browser-based interface for diagnostic device operations. With this platform, initializing devices and importing ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head ... bold recipes for Memorial Day entertaining that are sure to satisfy your guests’ ... fresh sliced meats and cheeses featured in these refreshingly balanced recipes are packed ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... On May ... (AHCA), which narrowly passed the U.S. House on May 4, would result in 23 ... expected under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... week that is focusing on the Peace Agreements being discussed by President Donald Trump ... in a race to try to speed up peace talks in the continuous battle ...
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using the ... can reconnect with America as it explores some of the best places to hike ... an inventive new place for a family vacation, and have discovered hiking. Many will ...
Breaking Medicine News(10 mins):